Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | GCK | P35557 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1207703 | 0.81 | ALDH1A1 (0.48) | KMT2AALDH1A1SMN1; SMN2KDM4EHTT | |
| SCHEMBL343646 | 0.81 | GCK (0.61) | KMT2AALDH1A1GCKSMN1; SMN2MEN1 | |
| SCHEMBL14419230 | 0.79 | KCNMA1 (0.60) | KMT2AALDH1A1GCKKDM4ELMNA | |
| SCHEMBL11711950 | 0.76 | VCAM1 (0.64) | KMT2AALDH1A1SMN1; SMN2MEN1LMNA | |
| SCHEMBL14419236 | 0.75 | KCNMA1 (0.64) | ALDH1A1KDM4ELMNAMAPTL3MBTL1 | |
| SCHEMBL10396627 | 0.74 | ALDH1A1 (0.58) | KMT2AALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL2616487 | 0.74 | KMT2A (0.49) | KMT2AALDH1A1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL11708532 | 0.74 | MAPT (0.61) | KMT2AALDH1A1KDM4EMEN1LMNA | |
| SCHEMBL13252870 | 0.73 | PLA2G7 (0.49) | KMT2AALDH1A1GCKMEN1LMNA | |
| SCHEMBL9686296 | 0.72 | ALDH1A1 (0.50) | KMT2AALDH1A1SMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20120101097-A9 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101097-A9 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120014997-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120014997-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110201610-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON | 2011-08-18 | — | — | US | disclosed |
| US-20110201610-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON | 2011-08-18 | — | — | US | disclosed |
| US-7932252-B2 | CCR9 chemokine receptor modulators; treating inflammatory and immune diseases; inhibit the binding of chemokines, such as TECK (thymus-expressed chemokine), to the CCR9 receptor; 1-arylsulfonamido-2-aryl(alkyl)benzene compounds | CHEMOCENTRYX, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080161345-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014997-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | KMT2A 2760/4885ALDH1A1 1655/4885GCK 3574/4885 |
| US-20110201610-A1 | ARYL SULFONAMIDES | CCR2, CCL2, CX3CR1 | KMT2A 2610/4885ALDH1A1 1258/4885GCK 2870/4885 |
| US-20150080351-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | KMT2A 2760/4885ALDH1A1 1655/4885GCK 3574/4885 |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | KMT2A 2576/4885ALDH1A1 1572/4885GCK 3476/4885 |
| US-20090163498-A1 | Aryl Sulfonamides | CCR9, CCR1, CCR2 | KMT2A 2760/4885ALDH1A1 1655/4885GCK 3574/4885 |
| US-20080161345-A1 | Aryl Sulfonamides | CCR2, CCL2, CX3CR1 | KMT2A 2610/4885ALDH1A1 1258/4885GCK 2870/4885 |
| US-20120101097-A9 | ARYL SULFONAMIDES | CCR2, CCL2, CX3CR1 | KMT2A 2610/4885ALDH1A1 1258/4885GCK 2870/4885 |
| US-20130267492-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | KMT2A 2760/4885ALDH1A1 1655/4885GCK 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.